JSF 4444
Alternative Names: JSF-4444Latest Information Update: 13 Sep 2023
At a glance
- Originator Collaborations Pharmaceuticals; Rutgers
- Class Antibacterials; Furans; Heterocyclic compounds; Naphthalenes; Nitro compounds; Small molecules
- Mechanism of Action Bacterial growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Gonorrhoea
Most Recent Events
- 18 Aug 2023 JSF 4444 is available for licensing as of 18 Aug 2023. https://www.collaborationspharma.com/partnerships
- 13 Jul 2020 Early research in Gonorrhoea in USA (unspecified route)
- 13 Jul 2020 Antimicrobial and pharmacokinetic data from early research in Gonorrhoeae released by Collaborations Pharmaceuticals